Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization

Anthony J. Dalby, Shmuel Gottlieb, Derek D. Cyr, Erik Magnus Ohman, Darren K. McGuire, Witold Ruzyllo, Deepak L. Bhatt, Stephen D. Wiviott, Kenneth J. Winters, Keith A.A. Fox, Paul W. Armstrong, Harvey D. White, Dorairaj Prabhakaran, Matthew T. Roe

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Objective Patients with diabetes mellitus (DM) presenting with acute coronary syndrome (ACS) and undergoing percutaneous coronary intervention (PCI) derived enhanced benefit with dual antiplatelet therapy (DAPT) with prasugrel vs. clopidogrel. The risk profile and treatment response to DAPT for medically managed ACS patients with DM remains uncertain. Methods The TRILOGY ACS trial compared aspirin + prasugrel vs. aspirin + clopidogrel for up to 30 months in non-ST-segment elevation (NSTE) ACS patients managed medically without revascularization. We compared treatment-related outcomes among 3539 patients with DM vs. 5767 patients without DM. The primary endpoint was a composite of cardiovascular death, myocardial infarction, or stroke. Results Patients with vs. without DM were younger, more commonly female, heavier, and more often had revascularization prior to the index ACS event. The frequency of the primary endpoint through 30 months was higher among patients with vs. without DM (24.8% vs. 16.3%), with a higher risk for those patients with DM treated with insulin vs. those treated without insulin (35.3% vs. 19.9%). There was no significant difference in the frequency of the primary endpoint by treatment with prasugrel vs. clopiodgrel in those with or without DM (Pint = 0.82) and with or without insulin treatment among those with DM (Pint = 0.304). Conclusions Among NSTE ACS patients managed medically without revascularization, patients with DM had a higher risk of ischemic events that was amplified among those treated with insulin. There was no differential treatment effect with a more potent DAPT regimen of aspirin + prasugrel vs. aspirin + clopidogrel.

Original languageEnglish (US)
Pages (from-to)156-166
Number of pages11
JournalAmerican heart journal
Volume188
DOIs
StatePublished - Jun 1 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization'. Together they form a unique fingerprint.

Cite this